MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis.
Díaz LA, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde MA, Perez D, Gómez J, Escarate R, Villalón A, Ramírez CA, Hernandez-Tejero M, Zhang W, Qian S, Simonetto DA, Ahn JC, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni AV, Rao PN, Salazar PG, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko KR, Romero GA, Pollarsky FD, Restrepo JC, Castro-Sanchez S, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero JP, Abraldes JG, Shah VH, Kamath PS, Arrese M, Singal AK, Bataller R, Arab JP.
Díaz LA, et al. Among authors: kulkarni av.
JHEP Rep. 2023 Mar 15;5(8):100727. doi: 10.1016/j.jhepr.2023.100727. eCollection 2023 Aug.
JHEP Rep. 2023.
PMID: 37456675
Free PMC article.